SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced that the
Company will present and host one-on-one meetings at the H.C.
Wainwright BioConnect Virtual Conference being held from
January 10 – 13, 2022.
Chief Executive Officer Saundra
Pelletier will provide an update on the commercialization of
Evofem's hormone-free contraceptive Phexxi® (lactic acid,
citric acid and potassium bitartrate) as well as the Company's
pipeline, including the ongoing Phase 3 clinical
trial evaluating EVO100 for the prevention of chlamydia and
gonorrhea in women and the recently announced Multipurpose
Prevention Technology (MPT) product candidate for indications
including the prevention of HIV in women.
The Company's presentation will be available for on demand
listening beginning at 7:00am ET on Monday,
January 10, 2022 through the H.C. Wainwright BioConnect
conference portal and via https://evofem.investorroom.com/HCWJan22
for 90 days.
To request a one-on-one meeting with Evofem during the
conference, please contact your H.C. Wainwright representative or
email ir@evofem.com.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (chlamydia, gonorrhea and HIV). The Company's first
FDA-approved product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free, on-demand
prescription contraceptive vaginal gel. It comes in a box of 12
pre-filled applicators and is applied 0-60 minutes before each act
of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-hc-wainwright-bioconnect-conference-301453189.html
SOURCE Evofem Biosciences, Inc.